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The cytokine erythropoietin (Epo) promotes erythropoietic progenitor cell proliferation and is required for
erythropoietic differentiation. We have found that the Epo gene is a direct transcriptional target gene of
retinoic acid signaling during early erythropoiesis (prior to embryonic day E12.5) in the fetal liver. Mouse
embryos lacking the retinoic acid receptor gene RXR have a morphological and histological phenotype that is
comparable with embryos in which the Epo gene itself has been mutated, and flow cytometric analysis
indicates that RXR-deficient embryos are deficient in erythroid differentiation. Epo mRNA levels are reduced
substantially in the fetal livers of RXR−/− embryos at E10.25 and E11.25, and genetic analysis shows that the
RXR and Epo genes are coupled in the same pathway. We furthermore show that the Epo gene is retinoic
acid inducible in embryos, and that the Epo gene enhancer contains a DR2 sequence that represents a retinoic
acid receptor-binding site and a retinoic acid receptor transcriptional response element. However, unlike
Epo-deficient embryos that die from anemia, the erythropoietic deficiency in RXR−/− embryos is transient;
Epo mRNA is expressed at normal levels by E12.5, and erythropoiesis and liver morphology are normal by
E14.5. We show that HNF4, like RXR a member of the nuclear receptor family, is abundantly expressed in
fetal liver hepatocytes, and is competitive with retinoic acid receptors for occupancy of the Epo gene enhancer
DR2 element. We propose that Epo expression is regulated during the E9.5–E11.5 phase of fetal liver
erythropoiesis by RXR and retinoic acid, and that expression then becomes dominated by HNF4 activity
from E11.5 onward. This transition may be responsible for switching regulation of Epo expression from
retinoic acid control to hypoxic control, as is found throughout the remainder of life.
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The generation of red blood cells is a necessary step in
vertebrate embryogenesis to progress from diffusion-lim-
ited growth to circulatory system-mediated growth. Red
blood cell production (erythropoiesis) involves the com-
mitment of a pluripotent hematopoietic stem cell to the
erythroid lineage, progression through erythroid BFU-E
and CFU-E progenitor cell stages, proerythroblast and
several types of erythroblast stages, and ultimately cul-
minating in the terminally differentiated erythrocyte.
During development, the location of erythropoiesis
shifts from the yolk sac in early embryos, to the fetal
liver in midgestation embryos, to the bone marrow and
spleen in late embryos and in postnatal life. Yolk sac
erythropoiesis is referred to as primitive erythropoiesis,
and is contrasted with definitive erythropoiesis, which
occurs in the fetal liver and throughout postnatal life. In
mouse embryos, yolk sac erythropoiesis initiates around
embryonic day 7.5 (E7.5) and ceases around E12.5, al-
though primitive erythrocytes persist for another 2 or
3 d. Erythropoietic activity initiates in the fetal liver
around E9.5 (Houssaint 1981; Palis et al. 1999), concur-
rent with the formation of the liver from the hepatic
diverticulum of the foregut, and ends late in gestation
when bone marrow erythropoiesis is initiated. Thus,
there is a brief window during which primitive and de-
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finitive erythroid cells coexist. In a normal mouse em-
bryo, 25% of the peripheral red blood cells at E12.5 are
derived from the fetal liver, whereas at E14.5, 90% of
these cells are of definitive origin (Mucenski et al. 1991;
Trimborn et al. 1999).
A number of cytokines are established to control the
erythroid differentiation process. Among these, the gly-
coprotein erythropoietin (Epo) has two critical roles in
definitive erythropoiesis. First, Epo contributes to the
survival and proliferation of definitive erythropoietic
progenitor cells in the fetal liver. Thus, in Epo−/− em-
bryos (Wu et al. 1995) the CFU-E and proerythroblast
populations are reduced several-fold in number. Second,
Epo is essential for these cells to reach the terminal steps
of definitive erythropoiesis, as no fetal liver-derived
erythroblasts or red blood cells form in Epo-deficient em-
bryos. Epo is not required for primitive erythropoiesis, in
that mouse embryos lacking Epo support yolk sac pro-
duction of red blood cells. Epo-deficient embryos die of
anemia at E13.5, as the yolk sac-derived red blood cells
that sustained development from E7.5–E12.5 die out and
are not replaced through definitive erythropoiesis. These
embryos show a characteristic small and pale fetal liver
at E12.5 and E13.5, a consequence of the absence of ter-
minal erythropoiesis. In histological sections, Epo defi-
ciency is manifest in a dramatic increase in cell death,
indicative of the aforementioned role in erythroid cell
survival. Mouse embryos lacking the Epo receptor (Wu et
al. 1995) or the JAK2 (Neubauer et al. 1998; Parganas et
al. 1998) component of the Epo receptor signal transduc-
tion cascade have a comparable midgestation anemic
phenotype.
The primary physiological regulator of Epo expression
in late embryos and in postnatal stages is oxygen tension
(Bunn et al. 1998). A mostly unknown hypoxia sensing
mechanism (Zhu and Bunn 1999) results in the activity
of the transcription factor HIF1 (hypoxia-inducible factor
1), which binds to a defined sequence in the 3 enhancer
of the Epo gene (Semenza et al. 1991) and initiates Epo
expression. In the fetal liver, Epo is expressed primarily
by hepatocytes (Koury et al. 1991), a property which is
conserved in hepatocellular carcinoma cell lines such as
Hep3B and HepG2, in which Epo expression is induced
in response to hypoxia (Goldberg et al. 1987). Adjacent to
the HIF1-binding site in the mouse Epo 3 enhancer is
the sequence TGACCTCTTGACCC, which is known as
a DR2 element because of the direct repeat of the hexa-
meric sequence TGACC(C/T) spaced by two nucleo-
tides. The Epo enhancer DR2 element substantially aug-
ments hypoxic induction of Epo gene reporter constructs
in transfected Hep3B cells, but is itself not responsible
for responding to hypoxia (Blanchard et al. 1992). HNF4
(hepatocyte nuclear factor 4) is currently believed to be
the primary factor that is responsible for Epo gene regu-
lation through the DR2 element (Bunn et al. 1998).
HNF4 is expressed in the fetal liver and postnatal kid-
ney, the two major sites of Epo expression, and introduc-
tion of an HNF4 expression construct in transfected
HeLa cells (which do not normally express HNF4) con-
fers hypoxic inducibility to an Epo reporter gene (Galson
et al. 1995). HNF4 appears to function synergistically
with HIF1 on the Epo enhancer by direct protein–protein
interaction and through the recruitment of transcrip-
tional coactivators (Bunn et al. 1998).
We have studied the biological function of the retinoic
acid receptor, which is comprised of a heterodimer of
RAR and RXR (Evans 1988). The RXR–RAR heterodimer
is well established to bind to and to transactivate
through generic DR2 elements; however, there has been
no prior evidence that retinoic acid or retinoic acid re-
ceptors are involved in Epo gene expression. Thus, reti-
noic acid treatment does not activate an Epo reporter
gene, nor alter hypoxic induction of the reporter gene, in
transfected Hep3B cells (Blanchard et al. 1992). We have
described previously a loss-of-function mutation of the
RXR gene (Sucov et al 1994) that results in embryonic
lethality at E14.5–E15.5 as a consequence of cardiac fail-
ure and placental dysfunction. However, transiently at
E11.5–E12.5 in RXR−/− embryos, there is a deficiency in
liver size and appearance that is strikingly similar to the
appearance of Epo-deficient embryos. The RXR fetal
liver phenotype is corrected from E13.5, such that when
these mutant embryos die of cardiac failure 1 or 2 d later,
their livers appear normal, unlike Epo−/− embryos, which
die at E13.5. In this study, we show that the initial ex-
pression of the Epo gene in the fetal liver is regulated by
retinoic acid receptors, and that the transient liver phe-
notype in RXR−/− embryos is a consequence of impaired
erythropoiesis. Furthermore, we show that RXR–RAR
and HNF4 are mutually competitive for activation
through the Epo enhancer DR2 element, and propose a
model in which regulation of Epo gene expression in the
fetal liver transitions from a retinoic acid- and RXR/
RAR-dependent mechanism to a HNF4- and hypoxia-de-
pendent mechanism.
Results
A transient reduction in fetal liver erythropoiesis
in RXR-deficient embryos
The initial steps of liver morphogenesis occur normally
in RXR-deficient embryos. Thus, in both wild-type and
RXR−/− embryos at E10.5, the endodermal hepatic cords
have become invaded by nonparenchymal mesoderm,
and endothelial cells line all sinusoids (Fig. 1a–f). How-
ever, over the next 2 d, the liver tissue of RXR−/− em-
bryos fails to expand normally. At E12.5, the liver is a
prominent and externally visible organ in the wild-type
embryo, but in RXR-deficient embryos is only margin-
ally evident (Fig. 1g). Upon dissection, the mutant livers
appeared to be organized properly, but contained ap-
proximately fourfold less tissue than wild-type litter-
mates (estimated by counting cell numbers, by measure-
ment of weight, and by reconstruction of liver tissue
volume from histological sections). The penetrance of
this phenotype at E12.5 was near 100% in inbred strains
and in a mixed background of C57Bl/6 and 129/Sv, and
more variable in other mixed strain backgrounds (data
not shown). No wild-type embryo was ever deficient in
Makita et al.
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the fetal liver in this regard. RXR-deficient embryos
were not growth retarded at E12.5, and with the excep-
tion of the liver deficiency, were otherwise mostly nor-
mal. The mutant embryos were also not obviously ane-
mic, although this is almost certainly because of suffi-
cient yolk sac-derived primitive erythropoiesis, which at
Figure 1. Liver morphology in RXR−/− embryos. (a–f) Morphology of liver tissue at E10.5. Richardson’s stained Epon sections of a
wild-type embryo (1 µm) (a) and littermate RXR−/− (d) embryo indicate two lobes of the developing liver flanking the stomach(s); the
overall morphology of the mutant tissue is normal. (b,c,e,f) Successively higher magnifications of a and d, respectively. (Asterisk)
Regions of tissue damage caused by histology artifact. (g,h) External appearance of littermate embryos at E12.5 (g) and E14.5 (h). The
arrows point to the externally apparent fetal liver in wild-type (wt) embryos at E12.5, and to the absence of evident tissue in RXR−/−
(ko) embryos at the same stage, whereas at E14.5, the fetal liver is prominent in embryos of both genotypes. An eye defect (Kastner
et al. 1994) can be noted in mutant embryos at both stages. (i–n) Morphology of liver tissue at E12.5. Both 5 µ paraffin hematoxylin
and eosin-stained sections (i,j,l,m) and 1 µ Richardson’s stained Epon sections (k,n) of different embryos are shown. Erythropoietic cells
(E) and hepatocytes (H) are morphologically distinguishable in wild-type tissue, although because of section angle or stage of cell cycle,
it is not possible to identify all cells by morphology. Note the widespread presence of pycnotic nuclei and cellular debris (horizontal
arrows) in RXR−/− tissue. It is uncertain as to what extent the debris is from erythroblasts or hepatocytes, but material from both cell
types may be represented. There is extensive vacuolization in the RXR−/− liver tissue (vertical arrows) that is present, but to a much
lesser extent, in wild-type tissue, and may be an indication of impending cell death, or aberrant hepatocyte glycogen or lipid storage.
Cellular debris and vacuolization are both seen in Epo−/− livers as well. Scale bars, b,e,j,k,m, and n, 100 µm; c and f, 20 µm.
Retinoic acid regulation of erythropoiesis
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E12.5 predominates peripheral circulation. Further-
more, mutant embryos at E12.5 are not yet altered in
placental (Sapin et al. 1997) or cardiac (Dyson et al. 1995)
function.
In wild-type E12.5 embryos, differentiating erythropoi-
etic cells can be identified in liver tissue on the basis of
their smaller size and highly condensed and deeply stain-
ing nuclei (Fig. 1j,k). These cells are likely to be eryth-
roblasts, as they are still nucleated, but are not stem or
progenitor cells, which are not strongly eosin positive.
Furthermore, these cells can be distinguished from cir-
culating erythrocytes, which at E12.5, are mostly yolk
sac derived and thus nucleated (primitive erythropoie-
sis), as the latter are found within sinusoids and vessels
enclosed by endothelium. Hepatocytes are recognizable
as larger cells with larger nuclei that stain more dif-
fusely. The overall appearance of the normal tissue was
highly uniform and organized.
In contrast, in littermate embryos lacking RXR, there
was a less compact organization in the mutant tissue
(Fig. 1m,n). Extended regions of cell death were promi-
nent, appearing as a loss of cellular structure with frac-
tured nuclei, with extensive cellular vacuolization and
with extracellular and subcellular granular material ap-
parent. Differentiating erythropoietic cells were less
common in the mutant fetal liver, suggestive of a defect
in erythropoietic survival and/or differentiation. Because
erythropoiesis is a major aspect of the growth of the liver
through midgestation, a deficiency in erythropoiesis is a
plausible explanation for the observation that RXR−/−
embryos are deficient in liver tissue at E12.5.
The liver deficiency in RXR−/− embryos is transient.
At E13.5, mutant embryos had externally visible liver
tissue, and at E14.5, the mass and volume of liver in
RXR−/− embryos was less than twofold reduced relative
to that of wild-type littermates, and was substantially
greater than what was present 2 or 3 d earlier (Fig. 1h).
Liver tissue from E14.5 mutant embryos was histologi-
cally normal (data not shown; see also Sucov et al. 1994).
The RXR−/− background is lethal at this time because of
cardiac defects (Sucov et al. 1994).
Flow cytometric analysis of fetal liver populations
To obtain a more precise description of the RXR-defi-
cient liver phenotype, we quantitatively characterized
the fetal liver cell population by flow cytometric analy-
sis (Fig. 2). For this analysis, we used the cell surface
markers c-kit and TER119; c-kit expression is high in
hematopoietic and erythroid progenitor cells and is re-
duced and ultimately eliminated as differentiation en-
sues, whereas TER119 is specifically expressed in eryth-
roblasts and erythrocytes, but not in BFU-E and CFU-E
populations (Ikuta et al. 1990; Kina et al. 2000). The
Figure 2. Flow cytometric analysis of fetal
liver cell populations. (a) Distribution pro-
files of cells expressing c-kit and TER119 are
shown for littermate wild-type and RXR−/−
embryos isolated at E12.25. The scale for
both axes is presented in log units. The des-
ignations of regions R1–R4 was made on the
basis of the presence of troughs between
peaks. R1 includes progenitor cells, R2 in-
cludes proerythroblasts, R3 represents
erythroblasts and erythrocytes, and R4 in-
cludes hepatocytes and potentially other
nonerythroid hematopoietic cells. Note the
concentration of cells in the R3 region in the
wild-type embryo, and the disproportionate
number of cells in the R1 and R2 regions in
the homozygous embryo. (b,c) Compiled
representation of cellular distributions, ex-
pressed in terms of total cell number per
fetal liver for each region. (b) Cellular distri-
butions at E12.25. (c) Cellular distributions
at E14.25. (Solid bars) Wild-type plus hetero-
zygous embryos; (hatched bars) RXR ho-
mozygous embryos; error bars, ±S.E.M.
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population of cells that is positive for both markers is
believed to be at the proerythroblast stage. The double-
negative cell population includes hepatocytes and differ-
entiated nonerythroid hematopoietic cells, although the
latter population is insignificant at E12.5 as almost all
hematopoiesis is devoted to erythropoiesis at this stage.
A depiction of the distribution of fetal liver cell popu-
lations (expressed in terms of normalized frequency per
50,000 fetal liver cells) from a wild-type embryo at
E12.25 and from a littermate RXR−/− embryo with a
prominent phenotype is shown in Figure 2a. In wild-type
embryos, the majority of cells were found in the c-kit
negative, TER119-positive category (region 3 [R3] in Fig.
2a), representing erythroblasts and erythrocytes. How-
ever, in mutant embryos, a disproportionate percentage
of cells were found in regions 1 and 2, with a compen-
satory reduction in the percentage of cells in the R3
population. It should be noted that the R3 population in
both wild-type and mutant livers is contaminated by
yolk sac-derived red blood cells within hepatic blood ves-
sels, which are also c-kit negative and TER119 positive.
Consequently, the impairment of definitive erythropoi-
etic differentiation in mutant liver is even more severe
than suggested by the data shown in Figure 2.
We analyzed a total of 37 fetal liver samples from 5
different litters of embryos isolated at E12.25, represent-
ing 13 wild-type, 11 heterozygous, and 13 RXR homo-
zygous embryos. The compiled results, expressed in
terms of the absolute number of cells in each category
per fetal liver, are shown in Figure 2b. Because of the
decrease in total cell number in mutant embryos (3.4-
fold average decrease for the 5 litters of Fig. 2), there was
a 2.4–2.6-fold decrease in the total number of cells in the
R1, R2, and R4 populations, despite an increase in the
normalized frequency of cells in these categories. How-
ever, the R3 population of differentiating erythroid cells
was compromised to a much greater degree (5.2-fold). Of
the 3.4-fold reduction in total fetal liver cell number in
mutant embryos relative to wild-type and heterozygous
embryos, 90% of this reduction occurs in the hemato-
poietic population (R1–R3), and 59% occurs specifically
in the erythrocyte (R3) population. As noted above, this
is a minimum estimate, because of the presence of con-
taminating primitive erythrocytes in both samples.
These results show a modest reduction in erythroid
progenitor cell populations, and a more severe block in
erythropoietic differentiation, in RXR−/− embryos at
E12.25. An independent assessment of erythroid progeni-
tor cells at E12.5 in a colony outgrowth assay indicated a
comparable frequency of BFU-Es in wild-type (75 ± 18
per 105 nucleated fetal liver cells) and mutant (67 ± 8)
tissue, which is consistent with the flow cytometric
analysis. The cellular phenotype and the histological ap-
pearance together indicate a defect in erythroid progeni-
tor cell survival and differentiation. The reduction in the
nonhematopoietic R4 cell population may be a second-
ary consequence of the reduced number of erythroid pro-
genitor cells and/or of the increased cell death present in
fetal liver tissue, or may represent some additional func-
tion of RXR in hepatocytes.
At E14.25, the RXR-deficient fetal liver was histo-
logically normal (data not shown), and contained no
more than a twofold reduction in total cell number. Flow
cytometric analysis of E14.25 fetal liver samples indi-
cated that all populations were fully or almost normal-
ized at this developmental time, both in frequency and
in absolute numbers (Fig. 2c), although there was still a
small residual decrease in the R3 population at this time.
Epo expression is reduced in RXR-deficient fetal liver
Because the fetal liver phenotype of RXR−/− embryos at
E12.25–E12.5 is very similar to that of Epo-deficient em-
bryos, we addressed whether a deficiency in Epo expres-
sion might underlie the RXR−/− phenotype. RNA was
isolated from fetal livers of individual littermate em-
bryos at developmental stages through midgestation. Be-
cause the amount of total RNA recovered per fetal liver
is small, we used a commercially packaged quantitative
RT–PCR assay in which 18S ribosomal RNA serves as an
internal standard; the amount of 18S rRNA amplifica-
tion product is attenuated by the inclusion of compe-
timer oligonucleotides that are titrated to ensure that
the level of amplification of the 18S rRNA and Epo prod-
ucts are in a linear range. We found (Fig. 3a) that Epo
mRNA levels were reduced ninefold relative to wild-
type embryos at E10.25 (the earliest time point sampled).
However, at E12.25 there were equal levels of Epo mes-
sage in knockout and wild-type liver samples (Fig. 3b).
We anticipate that there is a lag of ∼2 or more d between
the onset of Epo gene expression and the phenotypic con-
sequences of that expression, representing the time nec-
essary for proliferation and differentiation of erythroid
progenitor cells (e.g., it takes 2–3 d for CFU-E erythroid
progenitor cells to differentiate in vitro). Thus, the sub-
stantially reduced level of Epo mRNA expression in
RXR-deficient fetal liver at E10.25 is consistent with a
failure in the survival, proliferation, and differentiation
of erythroid progenitor cells as evaluated at E12.25,
whereas normal Epo expression at E12.25 is consistent
with the phenotypic recovery and normal appearance of
the fetal liver in RXR−/− embryos at E14.25, as observed
(Figs. 1 and 2). Note that the substantial reduction in Epo
expression at E10.25 occurs at a time when the overall
morphology of the mutant liver tissue is normal, and
that the normal expression at E12.25 occurs in tissue
that is highly dysmorphic but soon to recover (Fig. 1). At
times between E10.25 and E12.25, we observed an inter-
mediate level of Epo expression in RXR−/− embryos (i.e.,
a threefold reduction at E11.25) and an intermediate
level of tissue dysmorphology (data not shown).
To demonstrate that the deficiency of Epo expression
at E10.25 is a specific effect, the expression of other
genes was investigated. HNF3 is a transcription factor
that is expressed in definitive endoderm (plus other non-
hepatic tissues), including hepatocytes from the onset of
hepatogenesis. Albumin is a structural protein gene that
is exclusively expressed in hepatocytes. As noted above,
c-kit is expressed in hematopoietic stem and erythroid
progenitor cells. As shown in Figure 3c, all three genes
Retinoic acid regulation of erythropoiesis
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were comparably expressed in the E10.25 liver of
RXR−/− embryos. Normal expression of c-kit also shows
that hematopoietic stem cells have colonized the liver of
RXR−/− embryos at E10.25 in an apparently normal
manner, at least to the extent that c-kit is a reliable
marker of this population. Thus, the reduction in Epo
expression seen in RXR−/− embryos is a specific effect
and not an indirect consequence of globally altered fetal
liver gene expression. Epo expression in the placenta and
yolk sac, the two major non-hepatic sites of Epo expres-
sion, was unaltered in RXR−/− embryos (Fig. 3d), indi-
cating that the phenotype is specific to the liver.
RXR and Epo are epistatically related
The results described above suggested that the Epo gene
might be downstream of RXR in a common genetic
pathway. To further confirm this model, we evaluated
embryos that were heterozygous at both the RXR and
Epo loci. Embryos that were heterozygous at either locus
individually were normal (see below), which indicates
that fetal liver hematopoiesis is insensitive to a 50%
reduction in the amount of RXR or Epo protein. If
RXR is a regulator of Epo expression prior to E12.5,
then reduction of Epo gene dosage by half, coupled with
a reduced transactivation of the remaining allele by the
reduced level of RXR, might bring the level of Epo ex-
pression to below a threshold level such that a pheno-
type might result. In genetic terms, the evaluation of
such double heterozygotes (or trans-heterozygotes;
Avery and Wasserman 1992) is a way of determining if
the RXR locus is a genetic enhancer of the Epo mutant
phenotype.
Epo−/+ mice were mated to RXR−/+ animals to obtain
embryos at E12.0 that were either wild-type, single het-
erozygotes, or double heterozygotes, from which fetal
liver samples were analyzed as above by flow cytometry
with c-kit and TER119. These embryos were isolated at
a slightly earlier stage relative to those described above
(Fig. 2), on the basis of RNA analyses (Fig. 3a,b), which
suggested the likelihood of a more significant response
with younger embryos. In embryos singly heterozygous
for either the RXR or the Epo gene mutations, there was
no significant decrease in total fetal liver cell number,
and the distributions of the R1–R4 populations were
comparable with wild-type littermates. In contrast, in
double heterozygous embryos, there was a slightly less
than twofold decrease in total fetal liver cell number,
Figure 3. Epo expression is specifically reduced in early RXR−/− fetal liver and is retinoic acid inducible. Fetal liver samples were
analyzed by relative RT–PCR, using 18S RNA as an internal standard. Varying the ratios of 18S primers ensures that a linear range is
achieved for this product; for assays in which this titration is not shown, prior amplifications established the linear range of ampli-
fication. (a) Analysis of fetal liver samples from E10.25 littermate embryos. (b) Analysis of fetal liver samples from littermate E12.25
embryos. (c) Relative RT–PCR analysis of HNF3, albumin, and c-kit expression in E10.25 and E12.25 fetal liver tissue. 18S RNA
amplifications are not shown but were equal between corresponding lanes. Long and short exposures of the same gel for the albumin
product are both shown to point out comparable amplification from wild-type and RXR−/− samples at both time points. Quantitation
of c-kit amplification relative to 18S RNA amplification indicated that at E12.25 there is a modest (1.6-fold) increase in the abundance
of this message in mutant tissue relative to wild type, which is consistent with flow cytometry analysis. (d) Epo expression in placenta
and yolk sac of E10.25 wild-type and RXR−/− embryos. (e) Analysis of fetal liver samples from E10.0 wild-type embryos cultured in
vitro for a further 9 h in the absence or presence of retinoic acid. (f) Epo expression in wild-type and RXR−/− hepatocytes isolated from
E10.25 and E12.25 embryos and cultured without and with retinoic acid.
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and about the same decrease in the normalized fre-
quency of cells specifically in the R3 population, result-
ing in a decrease in the total number of cells in the R3
population of greater than threefold (Fig. 4). The R1, R2,
and R4 populations were only marginally altered in the
double heterozygous background. Double heterozygous
embryos were visually apparent at the time of isolation
as being compromised in their fetal livers (data not
shown). Thus, this analysis shows that the Epo and
RXR genes are both components of a common genetic
pathway, as there is phenotypic synergy when the het-
erozygous mutations are combined. The observation
that Epo message levels are reduced in RXR−/− embryos
(Fig. 3) suggests that the Epo gene lies downstream of
RXR in this pathway. Furthermore, this analysis
strongly suggests that the morphological deficiency of
E12.5 RXR−/− embryos is a direct effect of the decreased
level of Epo expression seen earlier in development,
rather than an indirect or secondary consequence of
other manifestations elsewhere in the embryo.
The Epo gene is retinoic acid responsive in embryos
RXR is a heterodimeric partner for multiple nuclear
receptors in complexes that are activated by a variety of
ligands. In principle, the absence of RXR could interfere
with normal transcriptional activation mediated by any
of these partner receptors and their ligands. Therefore,
we asked whether the Epo gene is ligand inducible by
any of the known compounds that activate RXR partner
receptors. For this purpose, wild-type embryos were iso-
lated at E10.0 intact within their yolk sacs and cultured
in vitro (see Materials and Methods) in the presence of
various ligands for 9 h. Of those tested, only retinoic acid
treatment resulted in an induction of Epo gene expres-
sion (Fig. 3e); ligands for the thyroid hormone receptor
(TR), bile acid receptor (FXR), fatty acid receptor
(PPAR), and pregnane/steroid receptor (PXR) all failed
to induce or only marginally induced Epo gene expres-
sion (data not shown).
To confirm the role of RXR in this process, we iso-
lated primary fetal liver cells (enriched for hepatocytes)
from individual embryos at E10.25 and cultured in the
presence or absence of retinoic acid. RA treatment in-
duced Epo expression in wild-type cells but not in cells
isolated from RXR-deficient embryos (Fig. 3f). There
was a higher basal level of expression in untreated wild-
type cells relative to untreated RXR−/− cells, whichmay
be a consequence of the low level of retinoids present in
the serum used to culture the fetal liver cells and con-
sequent activation of Epo expression in wild-type cells.
At E12.25, primary hepatocytes from embryos of both
genotypes expressed Epo at equivalent levels, and in nei-
ther case was Epo expression induced by RA treatment.
Thus, the Epo gene is RA inducible in E10.25 hepato-
cytes in a RXR-dependent manner, whereas the gene is
refractory to RA treatment at E12.25 regardless of RXR
genotype.
The Epo enhancer contains a retinoic acid response
element
The results described above are consistent with the Epo
gene being a direct target of RXR transactivation during
the early phase of liver development. We next asked
whether a luciferase reporter gene utilizing the Epo gene
promoter and enhancer was retinoic acid responsive in a
transfection assay. The reporter gene we used, called
wtEpo–LUC, contained the sequences from −411 to +10
of the mouse Epo gene promoter, plus a 96-bp fragment
containing the Epo gene enhancer (including the HIF1-
binding site and the DR2 element). This construct was
only marginally active in transfected normoxic Hep3B
cells, and was not retinoic acid inducible. However, un-
der hypoxic (1% O2) conditions, this reporter gene was
inducible by retinoic acid treatment (Fig. 5a). Because
DR2 elements are known as retinoic acid response ele-
ments, we asked whether retinoic acid responsiveness
was conferred through this sequence. When this site was
mutated, the Epo promoter/enhancer reporter gene was
no longer responsive to retinoic acid (mutEpo–LUC con-
struct; Fig. 5a).
We next addressed whether the enhancer DR2 element
functions as a RXR–RAR-binding site and as a retinoic
acid response element. Gel shift assays (Fig. 5b) using in
vitro-translated RXR and RAR protein showed that
neither protein alone bound to the Epo DR2, but together
the RXR–RAR heterodimer formed a specific complex on
this element that was competed by unlabeled DR2 se-
quences from the human and mouse Epo genes, but not
by unlabeled nonspecific competitor sequence. The hu-
man sequence contains a single base change relative to
the mouse (the mouse sequence is TGACCTCTT
GACCC; the human sequence changes the underlined T
to a C), and the human sequence is approximately four-
Figure 4. Epistasis analysis of RXR and Epo gene function.
The compiled representation of cell distributions in E12.0 wild-
type (n = 3), RXR heterozygous (n = 6), Epo heterozygous
(n = 4), and RXR/Epo double heterozygous (n = 3) fetal liver
samples from three litters is expressed in terms of total cell
number per fetal liver for each region, similar to Fig. 2.
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fold lower in affinity for RXR–RAR binding, consistent
with the known sequence requirements for DNA recog-
nition by retinoic acid receptors.
A reporter gene (4xDR2-TK-LUC) was prepared by in-
sertion of four copies of the mouse Epo DR2 element
into a minimal thymidine kinase promoter–luciferase
construct. The element was multimerized to maximize
responsiveness, a well-known requirement when the
minimal TK promoter is used in transfection studies; we
also assayed a reporter construct containing a single DR2
element with comparable, although less dramatic, re-
sults (data not shown). In CV-1 cells, which express a
very low level of endogenous nuclear receptors, this re-
porter gene was not basally active and was not retinoic
acid inducible. However, when RXR and RAR expression
vectors were cotransfected into these cells, the reporter
gene was dramatically induced by retinoic acid treat-
ment (Fig. 6a). Thus, as shown by gel shift and transfec-
tion assays, the DR2 element in the Epo gene 3 en-
hancer is a bonafide retinoic acid response element.
Competitive regulation of the Epo enhancer DR2
element by RXR–RAR and HNF4
In Hep3B cells, the chromosomal Epo gene is inducible
by hypoxia (unlike in CV-1 cells), and therefore repre-
sents a more authentic context for examination of Epo
gene expression. Hep3B cells express endogenous RXR
and RAR (see below). In our initial transfection assays,
the 4xDR2-TK-LUC reporter gene was only modestly in-
duced by RA treatment, although we found that we
could increase responsiveness by increasing the amount
of cotransfected RXR and RAR expression vector (Fig.
6b). We suspected that the known high level in Hep3B
cells of HNF4, which is already established to bind as a
homodimer to the Epo enhancer DR2 element (Galson et
al. 1995), might interfere with transactivation by the ret-
inoic acid receptor RXR–RAR heterodimer. To confirm
this model, we made use of a dominant-negative HNF4
construct (dnHNF4), in which a mutation in the DNA
binding domain renders the encoded protein fully able to
dimerize with wild-type HNF4, but the dimeric complex
is unable to bind DNA (Taylor et al. 1996). Introduction
of dnHNF4 alone allowed significant (ninefold) RA-in-
ducible transactivation of the reporter gene through en-
dogenous RA receptors, and cotransfection of dnHNF4
with RXR and RAR expression vectors resulted in syn-
ergistic activation of reporter gene activity (Fig. 6c).
Thus, in Hep3B cells, the Epo gene enhancer DR2 ele-
ment is transactivated by retinoic acid receptors, in a
manner that is inhibited by HNF4. We obtained similar
results in primary E18.5 fetal hepatocytes (Fig. 6d).
In CV-1 cells, introduction of dnHNF4 did not alter
expression of the reporter gene (data not shown), consis-
tent with the absence of endogenous HNF4 expression in
these cells. However, by cotransfecting wild-type HNF4
expression vector into CV-1 cells, we were able to de-
crease the ability of RXR–RAR to transactivate through
the Epo enhancer DR2 element (Fig. 6e). Thus, the ac-
tivity of this reporter gene is titratable by adjusting the
relative levels of HNF4 and RXR–RAR.
Finally, we asked whether retinoic acid responsiveness
of the Epo gene promoter/enhancer was also inhibited by
HNF4. In transfected hypoxic Hep3B cells, the presence
of dnHNF4 allowed a fivefold responsiveness to RA of
the wtEpo–LUC reporter via endogenous receptors, and
cotransfection of RXR–RAR and dnHNF4 together re-
sulted in an even greater response (Fig. 6f). Collectively,
these results indicate that HNF4 and RXR–RAR are mu-
tually competitive for recognition and occupancy of the
Epo enhancer DR2 element.
Figure 5. The Epo gene is retinoic acid responsive through the
enhancer DR2 element. (a) Transfection analysis. The wild-type
Epo promoter/enhancer reporter gene construct (wtEpo-LUC) or
a variant in which the DR2 element was mutated (mutEpo-
LUC) were cotransfected with RXR and RAR expression con-
structs into Hep3B cells under normoxic conditions or under
hypoxic conditions (1% oxygen) in the absence or presence of
10−6 M all trans RA, and cultured for 24 h. Luciferase activity
was normalized to -galactosidase activity. (b) Gel shift analy-
sis. In vitro-translated human RXR and RAR protein was used
under standard conditions with labeled probe representing the
human Epo gene DR2 sequence. (Lane P) is probe alone; (lane 1)
mock in vitro translation only; (lane 2) RXR only; (lane 3)
RAR only; (lanes 4–10) RXR plus RAR. Cold competitor
oligonucleotides included were a 10× and 50× molar excess of
the mouse Epo enhancer DR2 (lanes 5,6), 10× and 50× excess of
the human Epo enhancer DR2 (lanes 7,8), or 10× and 50× excess
of an irrelevant sequence (a loxP sequence) of the same length
(lanes 9,10). The arrow indicates the bound RXR–RAR complex.
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Discussion
The period between E9.5 and E12.5 in the mouse embryo
is a particularly critical time in hematopoiesis, as this is
when the embryo transitions from yolk sac (primitive) to
fetal liver (definitive) hematopoiesis. We have found that
the initial phase of erythropoiesis in the fetal liver is
acutely dependent upon RXR function. In RXR−/− em-
bryos prior to E12.5, erythroid differentiation in the fetal
liver is severely compromised, although this deficiency
does not cause any apparent consequence in other parts
of the embryo as there is adequate provision of primitive
red blood cells from the yolk sac (this process appears to
be unaffected by RXR gene mutation). As shown in this
study by genetic and molecular approaches, the fetal
liver phenotype prior to E12.5 is accounted for by a de-
crease in the level of Epo expression. Thereafter, control
of hematopoiesis becomes independent of RXR func-
tion; Epo expression is normal in these later embryos,
and erythropoiesis is restored to normal as well.
Based on results described in this study, we propose
that the initial expression of Epo in the fetal liver, from
E9.5 through E11.5, is under retinoic acid control. The
transduction of this retinoic acid signal requires RXR,
and occurs by occupancy of and transactivation through
the DR2 element in the Epo gene 3 enhancer. Most
probably, the active complex is a heterodimer of RXR
with any of the RARs, as all three RAR genes are ex-
pressed in the early fetal liver (Dolle et al. 1990), and
there is no known erythropoietic phenotype in any
single or double RAR gene mutations (Mendelsohn et al.
1994), although it is possible that the phenotype de-
scribed in this study could have been overlooked. In the
absence of RXR, Epo gene expression is reduced sub-
stantially, resulting in a deficiency in the expansion and
differentiation of erythroid progenitors within the fetal
liver. Starting around E11.5 and continuing for the re-
mainder of fetal liver erythropoiesis, HNF4 activity sup-
plants retinoic acid receptor function in controlling ex-
pression of the Epo gene, thereby restoring normal levels
of Epo gene expression and promoting the recovery of the
transient liver defect in RXR−/− embryos.
Figure 6. HNF4 is competitive with RXR–RAR for occupancy of the Epo enhancer DR2 element. The indicated reporter genes were
transfected into CV-1 cells (a,e), Hep3B cells (b,c,f), or primary E18.5 fetal hepatocytes (d) under normoxic conditions (a–e) or hypoxic
conditions (f) in the presence or absence of 10−6 M all trans RA, with cotransfected receptor expression plasmids as indicated. Numbers
indicate micrograms of transfected DNA.
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Our model is bolstered by genetic analysis of HNF4
function. Conventional HNF4−/− embryos die at gastru-
lation with a deficiency in extraembryonic endoderm
(Chen et al. 1994). Very recently (Li et al. 2000), this
phenotype has been rescued through E12.0 by use of tet-
raploid aggregation procedures, in which extraembryonic
tissues are wild type in function and the embryo itself is
HNF4-deficient. HNF4-deficient embryos at E12.0 are
substantially compromised in fetal liver Epo expression,
demonstrating that HNF4 is a required regulator of Epo
gene expression at least from E12.0 onward. However,
the morphology and histology of HNF4−/− fetal liver at
E12.0 is normal, with apparently normal erythropoietic
differentiation. Epo expression in earlier stage HNF4−/−
embryos was not examined, but we predict that Epo ex-
pression must be normal in earlier embryos (i.e., at
E10.5), on the basis of the lack of histological liver defi-
ciencies in HNF4−/− embryos at E12.0 and the demon-
strated necessity (Wu et al. 1995) of normal Epo function
for normal liver histogenesis through E12.5. Thus, these
observations indicate that HNF4 is not required for
erythropoiesis during the early phase of liver develop-
ment, but is required for normal Epo expression in later
embryos, and support our model that RXR–RAR is the
critical regulator of erythropoiesis during the initial pe-
riod of erythropoiesis in the fetal liver.
We have presented evidence in this study that HNF4
and RXR–RAR can compete directly for occupancy of the
Epo enhancer DR2 element. These results resolve a long-
standing puzzling observation that the Epo enhancer
DR2 element, although being nearly canonical in se-
quence to other retinoic acid response elements, is not
retinoic-acid responsive in Hep3B cells (Blanchard et al.
1992). Thus, in Hep3B cells and in late-gestation hepa-
tocytes, HNF4 is present in stochiometric excess relative
to RXR–RAR, essentially preventing transactivation by
retinoic acid. These results also explain why the chro-
mosomal Epo gene itself is not RA inducible in the livers
of embryos older than E12.0 or in postnatal animals (data
not shown), although it is clearly so in younger embryos
(Fig. 3).
To explain the observation that expression of the Epo
gene transitions from RXR–RAR control to HNF4 con-
trol around E11.5, we favor a model in which Epo ex-
pression occurs in fetal hepatocytes. Accordingly, but for
reasons we have not yet defined, RXR–RAR is dominant
in activity over HNF4 prior to E11.5, but with HNF4
being dominant over RXR–RAR at times thereafter.
HNF4 protein may be less abundant in the earlier period,
its activity may be suppressed by modification or by li-
gand, or the context of the Epo promoter/enhancer prior
to E11.5 may favor the activity of RXR–RAR even in the
presence of excess HNF4 (possibly through some type of
interaction with HIF1, which binds to the hypoxic re-
sponse element immediately adjacent to the DR2 ele-
ment, or through differential interaction with transcrip-
tional coactivators).
There are two alternative models that bear consider-
ation. First, RXR function may occur outside of the
fetal liver, and in a secondary or indirect manner affect
Epo expression in the liver. Two feasible outside candi-
date tissues might be the heart and placenta, as there are
defects in both tissues in RXR−/− embryos, and the pla-
centa in particular has been recently suggested to influ-
ence definitive erythropoiesis in the fetal liver (Ihle
2000). However, the placental (Sapin et al. 1997) and car-
diac (Dyson et al. 1995) defects of RXR−/− embryos are
only first apparent at E12.5 and progressively worsen
with advancing age, unlike the erythropoietic phenotype
and the reduction in Epo expression which are most se-
vere prior to E12.5 and resolve thereafter. Furthermore,
there are no known defects of any type in RXR hetero-
zygous embryos that would account in an indirect man-
ner for the erythropoietic phenotype of RXR/Epo
double heterozygous embryos (Fig. 4). As a second alter-
native, Epo expression prior to E11.5 may occur in a non-
hepatocyte cell population of the fetal liver under RXR
control, and after E11.5 in hepatocytes under HNF4 con-
trol. We can exclude the hematopoietic and endothelial
lineages, as chimeric embryos comprised of RXR−/−
cells and Flk1−/− cells (the latter are unable to contribute
to these lineages; Shalaby et al. 1997) have no erythro-
poietic phenotype (C. Tran and H.M. Sucov, unpubl.),
although we cannot yet formally rule out the possibility
that RXRmight function in another nonhepatocyte lin-
eage.
It is of interest to speculate as to the developmental
logic that causes the Epo gene to be regulated transiently
by retinoic acid receptors before becoming dominated by
HNF4 activity. Because genetic analysis (Li et al. 2000)
shows that HNF4 does not control Epo expression prior
to E11.5, the availability of an alternative mechanism
(i.e., retinoic acid receptors) through which to activate
Epo gene expression from E9.5–E11.5 has two potential
adaptive benefits. First, this mechanism allows the ini-
tiation of erythropoiesis in the fetal liver ∼2 d (in the
mouse embryo; possibly longer in human embryos) ear-
lier than otherwise, which provides an earlier contribu-
tion of mature red blood cells in peripheral circulation as
the yolk sac-derived primitive erythrocytes are dying.
Second, in addition to promoting erythropoietic differ-
entiation, Epo also stimulates erythropoietic progenitor
cell proliferation, and this may be of even greater benefit
in establishing definitive hematopoiesis within the fetal
liver prior to the time (around E12.5–E13.5) when defini-
tive erythropoiesis is required for embryo viability.
Interestingly, occupancy of the DR2 element by HNF4
in the context of either the Epo promoter or the TK pro-
moter does not lead to a substantial transcriptional re-
sponse. That is, there was a fairly low basal level of ac-
tivity of the DR2-containing reporter genes in Hep3B
cells; this was also true in CV-1 cells transfected with
HNF4 expression plasmids. HNF4 is constitutively ac-
tive but is a relatively weak transcriptional activator,
particularly in certain promoter and cellular contexts
(Jiang et al. 1995; Sladek et al. 1999). This may explain
why Epo gene regulation during the E9.5–E11.5 period
has evolved to depend on the transcriptionally more po-
tent RXR–RAR heterodimer, assuming that a high level
of Epo expression is beneficial (see above). One clear con-
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sequence of the relatively weak transcriptional activity
of HNF4 is that Epo expression in the later stage liver is
not constitutive, as would occur if HNF4 was able to
basally activate expression, but is hypoxic-dependent via
the activity of HIF1. The transition from RXR–RAR con-
trol to HNF4 control may therefore serve to switch regu-
lation of Epo expression from a paracrine mode con-
trolled by local retinoic acid production to an environ-
mentally responsive mode controlled solely by oxygen
tension, as is found throughout the remainder of fetal
and postnatal life.
Materials and methods
Histology
Embryos were isolated at appropriate gestational stages and
genotyped retrospectively by analysis of yolk sac DNA. For he-
matoxylin/eosin staining, embryos were fixed in 10% phos-
phate-buffered formalin, paraffin embedded, sectioned at 5-µ
thickness, and stained and processed by standard procedures.
For Richardson’s stained samples, whole embryos or isolated
liver tissue were fixed in phosphate buffer containing 2% para-
formaldehyde and 2.5% glutaraldehyde, followed by 1% os-
mium tetroxide in 0.1 M cacodylate buffer, and then embedded
in Epon-812. The 1-µ sections were cut with a glass knife and
stained in a solution containing 0.5% methylene blue, 0.5%
azure II, and 0.5% borax.
Flow cytometry analysis
Fetal liver tissue was isolated by dissection from individual em-
bryos and dissociated by trituration in Hank’s balanced salt so-
lution containing 0.02% EDTA, 0.2% BSA, and 0.03% sodium
azide on ice. A total of 0.05–0.2 million fetal liver cells from
each sample were stained with monoclonal antibodies for sur-
face expression of c-Kit (2B8) and TER-119 (Ly-76) (both from
Pharmingen), after blocking FcII/III receptors by use of super-
natant from the 2.4G2 hybridoma. Two-color analyses were per-
formed on individual fetal liver samples by flow cytometry in a
Becton Dickinson FACScalibur. A total of 50,000 events were
collected per sample, and analyses performed after excluding
dead cells. Because the actual developmental stage varied by up
to half a day between litters at the same nominal stage, we
calculated within each litter the fold increase or decrease in
each category for mutant embryos relative to wild-type plus
heterozygote embryos, and then combined these fold changes
for all litters to generate a composite depiction of the normal
and mutant phenotypes.
Colony outgrowth assay
E12.5 fetal liver tissue was dissociated by trituration, and an
aliquot counted to determine nucleated cell number. Cells were
mixed with Methocult 3430 (Stem Cell Technologies, Vancou-
ver, Canada) and incubated 7 d, then stained with benzidine and
scored by the criteria of containing 20 or more cells, of which at
least 15% were benzidine positive.
Quantitative RT–PCR
Total RNA was extracted from individual fetal liver tissue by
guanidinium isothiocyanate extraction. A total of 1 µg of total
RNA was reverse transcribed in a 20-µL reaction containing 2
µL (100–500ng) of Random Decamer Primer (Ambion), 100 ng of
Epo gene-specific primer (5-GAGCAAGTTCGTCGGTCCA-
3), 0.5 mM dNTPs, and 200 units of M-MuLV Reverse Tran-
scriptase (GIBCO BRL) in First Strand buffer (50 mM Tris-HCl
at pH 8.3, 75 mM KCl, 3 mM MgCl2, and 5 mM DTT). The RT
reaction was diluted with water to 80 µL, and 1 µL was used for
PCR. To initially determine the linear range of Epo amplifica-
tion, PCR was performed with multiple samples in a 30-µL
reaction containing 100 ng of each Epo primer (Zimmermann
and Rich 1997), 5 µCi of [-32P]dCTP, and 2.5 units of Taq DNA
Polymerase (GIBCO) in PCR buffer [20% DMSO, 134 mM Tris
at pH 8.8, 33 mM (NH4)2SO4, 20 mM -mercaptoethanol, 6 mM
MgCl2, and 1 mM dNTPs] with the following parameters: 1 min
at 94°C, 2 min at 57°C, and 2 min at 72°C. The amplification
profile was examined at 3-cycle intervals from 14 to 44 cycles.
PCR products were separated by nondenaturing 4% polyacryl-
amide gel electrophoresis in 1 × TBE at 4°C, and signal intensity
was analyzed by PhosphorImaging (Molecular Dynamics). For
quantitative analysis of Epo transcripts level, PCR was per-
formed with the addition of 0.4 µM of 18S ribosomal RNA prim-
ers and varying amounts of competimer mixture (Ambion) as an
internal control. The varying ratios of 18S primers ensures that
a linear range is achieved for this product as well, and allows
comparison of Epo mRNA abundance between samples by mea-
surement of the intensity of the Epo and 18S products at any 18S
primer/competimer ratio in which linear amplification of both
products occurs. Amplification of other genes was done exactly
as above, except for substitution of primers for HNF3
(GGCCTACTCCTCTGTCCCTGTCAG and ATGCCAGCCA
CAGCACCGGGACTC), albumin (CCCCACTTAGCCTCTG
GCAAAAT and AGACTCATCGGCAACACACGTCT), or c-
kit (ACAGGAGCAGAGCAAAGGTG and CGACCACAAAG
CCAATGAGC). For in vitro whole embryo culture, wild-type
embryos were isolated at E10.0 intact within their yolk sacs and
cultured in DMEM with 50% FCS in the presence of 10−6 M all
trans retinoic acid or solvent alone with gentle agitation on a
rocker platform in a tissue culture incubator. Other compounds
tested and their final concentrations included thyroid hormone
(T3; 10−8 M), Wy14,643 (5 × 10−6 M), chenodeoxycholic acid
(10−4 M), and pregnenalone 16-carbonitrile (PCN; 10−5 M). Af-
ter 9 h, fetal liver tissue was isolated from these embryos and
processed as above. For primary cell culture, fetal liver tissue
was dissociated from individual embryos by trituration, and
plated in the presence of solvent only or 10−6 M all trans reti-
noic acid in replicate wells of rat tail collagen-coated dishes.
After 4 h of incubation, nonadherent cells were washed off and
adherent cells collected for analysis. These conditions enrich for
hepatocytes (HNF3-expressing) and decrease representation of
hematopoietic cells (GATA1-expressing).
Electrophoretic mobility shift assay
Double-stranded oligonucleotide probe containing the human
or mouse Epo DR2 element was labeled with [-32P]dCTP by
Klenow fill-in reaction. Preincubation was performed for 20min
on ice in a 19-µL reaction containing 150 ng of poly [d(I-C)] plus
60 ng of nonspecific single-strand oligomer in a binding buffer
(75 mM KCl, 7.5% glycerol, 20 mM HEPES, 0.1% NP40, 2 mM
DTT) in the presence or absence of 3 µL each of in vitro-trans-
lated hRXR and hRAR, followed by addition of 0.8 ng of
labeled probe and 20 min of further incubation on ice. DNA–
protein complexes (20 µL) were separated by 5% polyacrylamide
gel electrophoresis in 0.5× TBE at room temperature. Competi-
tion assays were performed in the presence of 8 ng (10×) and 40
ng (50×) of unlabeled human or mouse Epo DR2 sequences or a
nonspecific (loxP) sequence.
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DNA constructs
The wild-type Epo promoter enhancer reporter construct
(wtEpo-LUC) was made by insertion of a 420-bp XbaI–SmaI frag-
ment (positions 1–420 of GenBank M12482) representing the
sequences between −410 and +10 relative to the transcription
start site of the mouse Epo gene (Shoemaker and Mitsock 1986)
into a luciferase vector lacking other promoter sequence. The
original plasmid from which this fragment was obtained was
described in Wu et al. (1995). A 96-bp fragment (positions 399–
494 of GenBank L13456) containing the complete enhancer el-
ement as functionally defined previously (Pugh et al. 1991) was
prepared by PCR amplification, subcloned and validated by se-
quencing, and inserted as a single copy 5 of the promoter frag-
ment. To specifically mutate the DR2 element, an enhancer
fragment of the same length was prepared by PCR amplification
but using a primer with an altered DR2 sequence, which was
sequenced to confirm correct amplification and inserted 5 of
the Epo promoter fragment as above. The wild-type mouse DR2
element is TGACCTCTTGACCT; the mutant sequence is
TTCATTCTGGCTAA. To make 4xDR2-TK-LUC, a 39-bp frag-
ment containing the wild-type DR2 sequence was inserted as a
four- copy head-to-tail multimer into the HindIII site of a pa-
rental TK-LUC plasmid.
Transient transfection assays
CV-1 cells were cultured in DMEMwith 10% FBS and plated on
35-mm tissue culture dishes at 60% confluency. A total of 3 µg
of reporter plasmid plus 0.25 µg of CMX–-gal were cotrans-
fected by calcium phosphate precipitation in the absence or
presence of cotransfected CMX–hRXR, CMX–hRAR, or
pSG5-rHNF41 expression vectors. The total amount of CMX
promoter and total plasmid (5 µg) was adjusted by addition of
CMX–EGFP and pGEM4 plasmids, respectively. After a 16-h
incubation, the transfection medium was replaced with fresh
medium with or without 10−6 M all-trans retinoic acid (Sigma),
and cells were incubated for 24 h before harvest. Hep3B cells
were cultured in DMEM containing 10% FBS and plated into
35-mm tissue culture dishes at 80% confluency, and were trans-
fected using Lipofectin (GIBCO BRL). Lipofection was per-
formed for 14 h, followed by replacement with medium with or
without 10−6 M of all-trans RA, and cells were cultured another
24 h before harvest. For normoxic conditions, cells were cul-
tured in standard incubators. For hypoxic conditions, following
transfection and replacement of medium, cells were transferred
to a chamber that was flushed with 1%O2/5%CO2/94%N2,
then sealed and incubated for 24 h. Hypoxic medium was first
sparged before use, and CoCl2 was added at a concentration of
10−4 M. For all reporter gene assays, cells were rinsed with 1×
PBS and scraped with 250 µL of 1× PBS. Cell suspensions were
centrifuged and pellets were lysed in 50–100 µL of lysis buffer
(TROPIX) by freeze-thaw. A total of 10 µL of cell lysate was
assayed with the Luciferase Assay System (Promega), and with
the Galacto-Light Plus (TROPIX) assay system. Primary hepa-
tocytes were prepared by trituration of fetal liver tissue, plated
in rat tail type IV collagen-coated dishes in DMEM with 10%
FCS, allowed to adhere for 4 h, washed to remove nonadherent
hematopoietic cells, and then transfected by calcium phosphate
as above.
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Note added in proof
A recent report has described retinoic acid induction of chro-
mosomal Epo gene expression in P19 cells (Kambe, T., Tada-
Kambe, J., Kuge, Y., Yamaguchi-Iwai, Y., Nagao, M., and Sasaki,
R. 2000. Blood 96: 3265–3271).
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